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Abstract
TNFa is overexpressed in the adipose tissue of obese rodents and humans, and is associated with insulin resistance.
To more closely link TNF expression with whole body insulin action, we examined the expression of TNF by muscle,
which is responsible for the majority of glucose uptake in
vivo. Using RT-PCR, TNF was detected in human heart, in
skeletal muscle from humans and rats, and in cultured human myocytes. Using competitive RT-PCR, TNF was quantitated in the muscle biopsy specimens from 15 subjects
whose insulin sensitivity had been characterized using the
glucose clamp technique. TNF expression in the insulin resistant subjects and the diabetic patients was fourfold
higher than in the insulin sensitive subjects, and there was a
significant inverse linear relationship between maximal glucose disposal rate and muscle TNF (r 5 20.60, P , 0.02).
In nine subjects, muscle cells from vastus lateralis muscle
biopsies were placed into tissue culture for 4 wk, and induced to differentiate into myotubes. TNF was secreted into
the medium from these cells, and cells from diabetic patients expressed threefold more TNF than cells from nondiabetic subjects. Thus, TNF is expressed in human muscle,
and is expressed at a higher level in the muscle tissue and in
the cultured muscle cells from insulin resistant and diabetic
subjects. These data suggest another mechanism by which
TNF may play an important role in human insulin resistance. (J. Clin. Invest. 1996. 97:1111–1116). Key words: tumor necrosis factor • non–insulin-dependent diabetes mellitus • insulin resistance • obesity • quantitative reverse
transcriptase polymerase chain reaction (RT-PCR)

Introduction
The development of obesity is not completely understood; humans gain weight to variable degrees when presented with excess calories (1, 2), suggesting that individuals can defend
against obesity. In addition, insulin resistance accompanies
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nearly all patients who become obese, yet the relationship between adiposity and insulin sensitivity is not clear. One possible etiology for the insulin resistance of obesity is the production of the cytokine tumor necrosis factor a (TNFa).
Several studies have described the production of TNFa by
adipose tissue and demonstrated higher expression in the adipose tissue of insulin resistant, genetically obese rodents (3, 4).
These observations in rodents were essentially confirmed by
recent human studies, which demonstrated elevated TNF expression in the adipose tissue of obese subjects, and decreased
expression following weight loss (5, 6). Since TNFa is known
to induce insulin resistance in 3T3-L1 cells (7), TNFa could
function in an autocrine fashion to regulate insulin sensitivity
in adipocytes. In an attempt to reverse insulin resistance, a soluble TNF receptor-IgG chimeric protein was infused into fa/fa
rats, resulting in an increase in insulin-stimulated glucose uptake, along with an increase in autophosphorylation of the insulin receptor and insulin receptor substrate 1 (IRS-1) (3, 8).
These studies lead to several provocative conclusions regarding the interactions between adipose tissue and muscle.
Adipose tissue expressed higher levels of TNF, and the antiTNF infusion in the animals resulted in an increase in glucose
disposal (3). Because muscle accounts for most in vivo glucose
disposal (9), these data suggested that muscle responded to
anti-TNF treatment. In addition, the anti-TNF infusion resulted in an improvement in insulin receptor phosphorylation
in both adipose tissue and muscle (10). There are several possibilities for these effects on muscle. As suggested by Hotamisligil and Spiegelman (4), TNF produced by the adipose tissue
in, or surrounding, muscle may have caused insulin resistance
in muscle, and this peri-muscular adipose TNF may have been
inhibited by the anti-TNF antibodies. On the other hand, muscle, like adipose tissue, may itself express TNF, which would
then function in an autocrine fashion to inhibit insulin action.
As described herein, we have successfully measured TNF
expression in human and rat muscle, and demonstrate regulation of muscle TNF during changes in insulin sensitivity. These
studies suggest another potential mechanism for the increased
insulin resistance associated with obesity.

Methods
Patients and sample acquisition. Patients were recruited from the
outpatient clinics of the Indiana University School of Medicine, the
La Jolla VA Medical Center, and Cedars-Sinai Medical Center. This
protocol was approved by each institution’s respective IRB, and all
subjects gave informed consent to the procedures. The characteristics
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of the patients are shown in Tables I and II. In some of the patients,
insulin sensitivity was characterized using the hyperinsulinemic euglycemic clamp technique, as described previously (11, 12). In brief,
the glucose disposal rate was calculated on the basis of the glucose infusion rate during a primed continuous insulin infusion (600 mU?
m22?min21), corrected for changes in glucose pool size. Hepatic glucose output was assumed to be completely suppressed at the high insulin infusion rate (12). In all subjects, the studies were carried out for
at least 3 h, and the glucose infusion rate was stable for the final 60
min of the study. Glucose disposal rates were normalized per kilogram of lean body mass, determined by dual energy x-ray absorptiometry scanning. During the steady-state period, the serum glucose
was maintained between 4.4 and 5.0 mM, with a coefficient of variation of , 4%. Muscle biopsies were performed in subjects characterized with glucose clamps and used for quantitation of TNFa mRNA;
these subject groups are described in Table II. Euglycemic clamp data
were not available on the nine subjects recruited for muscle cell cultures, and these subject groups are described in Table I.
The human skeletal muscle samples were all obtained in the fasting state by needle biopsy of the vastus lateralis muscle and immediately frozen in liquid nitrogen. Human heart was obtained from the
left ventricular myocardium (interventricular septum, to avoid contamination by epicardial fat) of the explanted heart of transplant recipients. Cell lines (Chinese hamster ovary [CHO], and L6 muscle
cells) were obtained from the American Type Culture Collection
(Rockville, MD).
Cultured human muscle cells. Cultured cells from human skeletal muscle were obtained from two sources. Fetal myoblasts were obtained commercially (MyoPack®-Sk; Clonetics, San Diego, CA) and
differentiated into myotubes by the addition of 2% FBS after cells
reached 70% confluence, according to the instructions supplied by
Clonetics. In addition, myocytes were obtained by primary culture
from human muscle biopsies, as described previously (13). In brief,
each muscle biopsy yielded 250–400 mg of tissue, which was minced
and dissociated with three trypsin/EDTA treatments. Cells were pelleted and resuspended in medium (SkGM; Clonetics) with 2% FBS
and cultured in a 5% CO2 environment. After reaching 70–80% confluence, these cells were induced to form fused myotubes by changing
the medium to DME containing 2% FBS. Previous studies using fluorescent cell sorting, using an antibody directed against a muscle surface
antigen (5.1H111) (14), demonstrated that these cells were . 90%
myoblasts. In addition, these cells responded to insulin with an increase in glucose transport and glycogen synthesis (13).
Measurement of TNF mRNA levels using reverse-transcriptase
polymerase chain reaction (RT-PCR).1 To measure muscle TNF expression, a quantitative competitive PCR assay was developed, as described previously (6). Total RNA was extracted from muscle according to the method of Chomczynski and Sacchi (15), and the quality of
RNA was verified by ethidium bromide staining of rRNA bands on a
minigel. The primer sites for PCR were located at nucleotides 217 to
236, and 426 to 445 of the TNF cDNA. For rat muscle, as well as for
cell lines derived from rodents, slightly different primers were used.
The upstream primer was GCC ATT GGC CAG GAG GGC, and
the downstream primer was CGC CAC CAC GCT CTT CTG. 0.4 mg
of total RNA were added to increasing quantities of a cRNA construct, which contained a 49-bp deletion (16). After the reverse transcriptase reaction, PCR was performed for 35 cycles at 678C, and the
resulting ethidium bromide-stained gel was imaged using an Imagestore 5000 scanner, and analyzed using the Gelbase/Gelblot software
(Ultraviolet Products, Ltd., San Gabriel, CA). The ratio of TNF
product/cRNA standard was plotted against the number of copies of
cRNA added, to yield the equivalence point between cRNA and
TNF mRNA. Data were expressed as the “number of copies”/mg of

1. Abbreviations used in this paper: BMI, body mass index; GDR, glucose disposal rate; NIDDM, non-insulin dependent diabetes mellitus;
RT, reverse transcriptase.
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Figure 1. TNF mRNA in muscle cells and tissue. Using RT-PCR, the
predicted 229-bp TNF fragment was demonstrated in total RNA extracted from human skeletal and heart muscle, rat muscle (soleus),
cultured human myoblasts and cultured myocytes from human muscle biopsies (see Methods). Negative controls included CHO cells,
and L6 cells.

total RNA, where “number of copies” refers to the number of copies
of the cRNA added. PCR was negative when the reaction was performed without prior RT reaction, indicating a lack of contamination.
Western blotting of TNF protein. TNF was identified in the medium of cultured human muscle cells by Western blotting, using
methods described previously (6). Cells were grown to confluence
and differentiated into myocytes by the addition of DME containing
2% Fetal bovine serum. Serum-free medium was added and conditioned medium was collected 2 h later. Medium was concentrated
10-fold using Centricon Concentrators (Centricon-3; Amicon, Inc.,
Beverly, MA), and was then analyzed under denaturing conditions on
a 15% SDS polyacrylamide gel. After transfer to nitrocellulose, the
membrane was blotted with a 1:2,000 dilution of rabbit anti-TNF antiserum (generously provided by Dr. Carl Grunfeld), followed by
biotinylated anti–rabbit IgG (Sigma Chemical Co.), and streptavidinperoxidase (Promega, Madison, WI). The blot was developed with a
chemoluminescent peroxidase substrate (Promega). Quantitation
was performed by scanning the blot, and comparison with the Western blot image of known TNF standards.
Statistics. All data were analyzed non-parametrically, using the
Wilcoxon matched-paired sign rank test for paired data, and the
Mann-Whitney test for non-paired data. Linear regressions were performed using the Spearman rank-order correlation test.

Results
To determine whether TNF was expressed in human muscle,
RNA was extracted from a variety of muscle sources and RTPCR was performed as described in Methods. As shown in
Fig. 1, the predicted 229-base fragment for TNF was detected
in human skeletal and heart muscle, as well as in rat skeletal
muscle. Because muscle contains other cells besides myocytes,
TNF mRNA was measured in cultured myocytes. As shown in
Fig. 1, the TNF mRNA was detected in cultured myoblasts, as
well as in myocytes cultured from human muscle biopsies, as
described in Methods. Cells that contained no detectable TNF
using these methods included L6 cells, which is a rat muscle
cell line, and CHO cells.
Fig. 2 illustrates the use of quantitative RT-PCR for the
measurement of TNF mRNA from cultured myocytes. RNA
was extracted from myocytes prepared from control and diabetic subjects, and added to increasing quantities of the TNF

Figure 3. TNF mRNA levels in myocytes cultured from muscle biopsies of normal and diabetic subjects. Data are expressed in relation to
copies of cRNA added/mg total RNA. (Inset) TNF secretion into the
medium. Western blot of TNF from cultured muscle cells. Purified
TNF (1 ng) is shown alongside the medium from myocyte cultures
from a normal (lane 1) and a diabetic (lane 2) subject. *P , 0.05 vs.
normal.

Figure 2. Quantitation of TNF mRNA in muscle using RT-PCR. Total RNA was extracted from myocytes cultured from a normal subject, and a subject with diabetes. (A) Total RNA from each culture
was added to increasing quantities (as indicated) of a cRNA construct
that contained primer sites for human TNFa. RT-PCR of this cRNA
construct yielded a product that was 49 nucleotides shorter than the
PCR product generated from native human TNFa mRNA, and which
could therefore be distinguished on the gel. (B) The ratio of cRNA
standard/TNF product was plotted against the number of copies of
cRNA added, to yield the equivalence point between cRNA and
TNF mRNA. This figure is the plot of the gels from A. The equivalence point for the normal (nondiabetic) subject was 4.2 3 103 copies,
and for the diabetic patient the equivalence point was 27 3 103 copies, which refers to the number of copies of the cRNA added. Data
were expressed as the “number of copies”/mg of total RNA, which
yielded the values shown (7.97 3 103, and 54.9 3 103 copies/mg total
RNA for normal and diabetic, respectively).

cRNA, followed by RT-PCR. The PCR products derived from
the cRNA and TNF mRNA were easily distinguished on the
gel, and the ratio of the two products increased linearly with
addition of cRNA to the reaction. The equivalence point, at
which the amount of added cRNA-product was equal to the
amount of mRNA-product, was determined and expressed as
“number of copies”/mg of total RNA, where “number of copies” refers to the number of copies of the cRNA added. As can

be seen, the amount of TNF mRNA in the myocytes from the
diabetic patient was higher than the TNF mRNA in the normal subject.
Additional subjects were recruited for muscle biopsy and
subsequent primary culture of myocytes. The description of
these nine subjects (5 nondiabetic and 4 diabetic) is shown in
Table I. There was no difference in body mass index (BMI) between the control and diabetic subjects, and serum glucose,
Hgb A1C, and insulin levels were higher in the diabetics, as expected. After muscle biopsy, cells were placed into culture for
4 wk, and then differentiated into fused myotubes, as described in Methods. TNF mRNA expression was measured using RT-PCR, as described above. As shown in Fig. 3, myocytes
cultured from diabetic patients contained significantly more
TNF mRNA than myocytes from nondiabetic subjects. To
demonstrate that the TNF protein was produced by these cells,
the conditioned medium from these cells was collected, concentrated, and analyzed by Western blotting. As shown in Fig.
3 (inset), the 17-kD TNF band was identified from the cultured
human muscle cells. In addition to the 17-kD band, a fastermigrating species was identified, which probably represented
TNF breakdown product. The Western blot images were
scanned and compared to the TNF standard on the gel. Medium TNF immunoreactivity was 6.7760.01 ng/ml in cultures
from nondiabetic subjects, and was 14.0360.55 ng/ml in cultures from diabetic patients (P , 0.01).
In addition to measuring TNF in cultured myocytes, TNF
was measured in the muscle tissue of 15 subjects, who covered
a spectrum of insulin sensitivity, as defined by euglycemic
clamping. As shown in Table II, five of these subjects were insulin sensitive, with a mean, maximally stimulated glucose disposal rate (GDR) of 18.460.7 mg/kg per minute, whereas five
subjects were nondiabetic but relatively insulin resistant (mean
GDR 10.260.5 mg/kg per minute), and five subjects had non–
insulin-dependent diabetes mellitus (NIDDM), and a much
lower GDR (6.961.5 mg/kg per minute). As expected, the insulin resistant and diabetic subjects had higher fasting insulin
levels, and the diabetic subjects had higher fasting blood glucose levels, and were more obese.
TNF Expression by Muscle
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Table I. Subjects for Myocyte Primary Culture
n

Nondiabetic
Diabetic

M/F

5
4

5/0
4/0

Age

Insulin

FBG

Hgb A1C

BMI

yr

mU/ml

mg%

%

kg/m2

4663
5565

11.262.7
27.5612.9*

5.862.2
9.660.3*

30.063.2
30.861.9

97.463.8
183626.2*

*P , 0.05 vs. nondiabetic

TNF mRNA levels were measured from the muscle biopsy
specimens from each subject. As shown in Fig. 4, TNF mRNA
levels were significantly higher in both the insulin resistant
subjects, and the diabetic subjects. When the relationship between in vivo insulin action, as represented by the maximal
glucose disposal rate, and muscle TNF expression was analyzed, there was a significant linear relationship. As shown in
Fig. 5, increasing muscle TNF expression was associated with a
decreased in vivo glucose disposal rate (r 5 20.60, P , 0.02).
Thus, there was increased expression of TNF in both cultured
myocytes, and in muscle tissue from subjects with diabetes and
insulin resistance.

Discussion
TNF is a cytokine produced in large quantities by macrophages, and has long been associated with the cachexia of cancer and AIDS because of its many catabolic actions (17). In
adipocytes, these catabolic actions include a decrease in the activity of lipoprotein lipase (LPL) (18, 19), a decrease in the expression of the glucose transporter Glut4 (20), and an increase
in lipolysis, suggesting an increase in the activity of hormone
sensitive lipase (21). Recent studies have demonstrated that
TNF is expressed in adipose tissue, and is expressed at higher
levels in the adipose tissue of obese rodents and humans (3, 5,
6). Therefore, the production of TNF by adipose tissue could
be a local regulator of fat cell size, and the overproduction of
TNF in the adipocytes of obese mammals could limit adipocyte size through some combination of catabolic actions.
Additional studies have suggested that TNF is important in
the development of insulin resistance, both in obesity, and in
NIDDM. When a soluble TNF binding protein was infused
into fa/fa rats, which have high levels of adipose tissue TNF,
there was a 2–3-fold increase in insulin-stimulated glucose uptake, along with improved insulin receptor autophosphorylation in both adipose tissue and muscle (3, 10). Since muscle is
the main determinant of insulin-stimulated glucose uptake,
these findings indicated that the systemic inhibition of TNF affected in vivo insulin action, and therefore likely involved insulin action in muscle. There are several possibilities to explain

these changes involving muscle. Adipose tissue TNF may be
secreted into plasma, and plasma TNF may affect muscle insulin responsiveness. However, TNF levels in plasma are very
low, and cannot be reproducibly measured, even in patients
with obesity or metastatic cancer (5, 17, 22). Therefore, adipose TNF may not affect muscle in a traditional humoral fashion. Another possibility is an indirect effect, where adipose
TNF triggers other events, which ultimately lead to decreased
muscle insulin action. It is also possible that certain adipose tissue depots, which are in close proximity to muscle, secrete
TNF, which then affect muscle glucose transport in a paracrine
fashion (4).
As described herein, TNF was expressed by both rat and
human muscle, and was also expressed by muscle cells in culture. These data suggest that TNF could have been produced
by muscle cells and functioned in an autocrine fashion to inhibit muscle glucose transport. Hence, when TNF binding protein was infused into fa/fa rats (3, 10), it may have inhibited
muscle TNF, as well as inhibit TNF from other sources, such as
adipose tissue. However, in a previous study, TNF mRNA was
not detected in rat muscle by Northern blot (3). We demonstrated the presence of both the TNF mRNA, as well as the
TNF protein in cultured cells. The TNF detected in muscle
could not have been from contamination from adipose cells.
TNF was detected in heart muscle and rat skeletal muscle,
both of which were free of adipose tissue, and in cultured muscle cells. Although the muscle cells in culture contained . 90%
myocytes (13), it is possible that the cell of origin for TNF expression was a cell in muscle other than a myocyte. The level
of expression of TNF by muscle is lower than that in adipose
tissue, and therefore RT-PCR was used to measure TNF
mRNA levels in muscle.
TNF expression was increased in the muscle biopsy samples from subjects with insulin resistance, and there was a significant inverse relationship between TNF mRNA levels and
GDR. It is important to note that muscle TNF was increased in
insulin resistant non-diabetics, as well as in subjects with established NIDDM. Therefore, the elevated muscle TNF cannot
be a result of hyperglycemia and the diabetic milieu. This relationship between TNF and GDR was dependent on the inclu-

Table II. Subjects for Muscle Biopsy
n

Normal, insulin-sensitive
Normal, insulin-resistant
Diabetic

5
5
5

M/F

3/2
5/0
3/2

Age

GDR

Insulin

FBG

BMI

Body fat

yr

mg/kg per min

mU/ml

mg%

kg/m2

%

38.862.3
37.064.6
42.261.9

18.460.7
10.260.5‡
6.961.5‡

5.860.7
16.668.7
16.864.7

83.662.5
91.860.9*
199.3635.5‡

26.762.2
29.461.4
39.162.2‡

30.467.6
26.261.8
37.864.5

*P , 0.05 vs. normal, insulin sensitive; ‡ P , 0.02 vs. normal, insulin sensitive.
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Figure 4. TNF mRNA expression by human muscle. TNF mRNA
levels in muscle biopsy specimens from insulin sensitive, insulin resistant (nondiabetic), and diabetic subjects. *P , 0.05 vs. normal.

though the levels of TNF expression by muscle were low, they
may be sufficient to cause insulin resistance in an autocrine
manner in muscle. Because cultured muscle cells from diabetics continued to express higher levels of TNF, and because insulin resistant nondiabetics overexpressed TNF in muscle,
these data are consistent with TNF as a primary, or as an early
pathophysiologic marker of the insulin resistant state, and
could be part of the complex genetic syndrome characterized
phenotypically by obesity, insulin resistance, and NIDDM. On
the other hand, it is possible that the elevated TNF expression
is a response to the insulin resistant state, and that cells maintain this overexpression when cultured.
In summary, TNF was expressed by human muscle and myocytes in culture, and TNF expression was higher in the muscle
of subjects with insulin resistance and NIDDM. These data
suggest an important role for TNFa in the pathogenesis of human insulin resistance, as occurs in obesity and diabetes.
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Figure 5. Relationship between muscle TNF expression and insulin
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